The essential medicines list for a global patient population

被引：11

作者：

Robertson, J. ^{[1
]}

Hill, S. R.

机构：

[1] Univ Newcastle, Fac Hlth, Sch Med & Publ Hlth, Newcastle, NSW 2308, Australia

[2] World Hlth Org, Geneva, Switzerland

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 82卷 / 05期

关键词：

D O I：

10.1038/sj.clpt.6100392

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Thirty years after its inception, the role, audience, and contents of the global Essential Medicines List (EML) are reviewed. Challenges for decision makers in applying the principles of medicine selection based on efficacy, safety, burden of disease, and cost effectiveness are discussed and illustrated with recent decisions of the Expert Committee. Areas of controversy for decision makers are highlighted, and the advocacy role of the EML for both drug procurement and development of quality-assured products is described.

引用

页码：498 / 500

页数：3

共 13 条

[1] WHO estimates of the causes of death in children [J].

Bryce, J ;

Boschi-Pinto, C ;

Shibuya, K ;

Black, RE .

LANCET, 2005, 365 (9465) :1147-1152

[2] International Association for Hospice and Palliative Care list of essential medicines for palliative care [J].

De Lima, L. .

ANNALS OF ONCOLOGY, 2007, 18 (02) :395-U2

[3] The concept of essential medicines: lessons for rich countries [J].

Hogerzeil, HV .

BRITISH MEDICAL JOURNAL, 2004, 329 (7475) :1169-1172

[4] 25 years of the WHO essential medicines lists: progress and challenges [J].

Laing, R ;

Waning, B ;

Gray, A ;

Ford, N ;

't Hoen, E .

LANCET, 2003, 361 (9370) :1723-1729

[5] Essential medicines twenty-five years on: closing the access gap [J].

Quick, JD .

HEALTH POLICY AND PLANNING, 2003, 18 (01) :1-3

[6] Are drugs for rare diseases "essential"? [J].

Reidenberg, Marcus M. .

BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2006, 84 (09) :686-686

[7] Commentary: The pros and cons of essential medicines for rich countries [J].

Reidenberg, MM ;

Walley, T .

BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7475) :1172-1172

[8]

Ruxin J, 2005, LANCET, V365, P618, DOI 10.1016/S0140-6736(05)70806-0

[9] Rare essentials: drugs for rare diseases as essential medicines [J].

Stolk, Pieter ;

Willemen, Marjolein J. C. ;

Leufkens, Hubert G. M. .

BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2006, 84 (09) :745-751

[10] Learning from low income countries - Summary of webchat [J].

Twisselmann, B .

BRITISH MEDICAL JOURNAL, 2005, 330 (7489) :479-479

← 1 2 →